Where Particles Are Granulated Patents (Class 424/470)
-
Patent number: 8658207Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.Type: GrantFiled: August 13, 2007Date of Patent: February 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Wolfram Eisenreich, Thomas Friedl, Florian Sommer, Nantharat Pearnchob, Karl G. Wagner
-
Patent number: 8637079Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.Type: GrantFiled: January 30, 2008Date of Patent: January 28, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura
-
Patent number: 8617596Abstract: A process is provided for efficiently producing sustained-release tablets having superior sustained-release properties capable of inhibiting the initial elution of a drug and allowing the drug to be completely eluted after a prescribed amount of time has elapsed. A process for producing sustained-release tablets comprising: dry granulating a mixture composed of a hydroxyalkyl cellulose (A) having a viscosity of 1 to 50 mPa·s in a 2% by mass aqueous solution at 20° C., a hydroxyalkyl cellulose (B) having a viscosity of 100 mPa·s or more in a 2% by mass aqueous solution at 20° C., an active ingredient and an additive, and forming the resulting granules into tablets.Type: GrantFiled: April 10, 2007Date of Patent: December 31, 2013Assignee: Nippon Soda Co., Ltd.Inventors: Takeshi Honma, Kenji Furukawa
-
Patent number: 8568767Abstract: The present invention provides a chewable composition containing granules of water-soluble dietary fiber. The chewable composition has highly agreeable organolpetic properties and is consumable without the need of an ingestion aid.Type: GrantFiled: January 9, 2013Date of Patent: October 29, 2013Assignee: Novartis AGInventors: Nils William Ahlgren, Ronald Lee Dahl, Monte Lee Friesen, Alexander Mark Schobel
-
Patent number: 8557283Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 11, 2012Date of Patent: October 15, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
-
Patent number: 8551915Abstract: The present invention provides a product for agricultural use in the form of granules or pellets, characterized by comprising at least 30% (w/w) of vinasses and/or sludge measured as a dry extract of vinasses and/or sludge, and an organic or inorganic solid support. In addition, the present invention provides a procedure for producing said product, its use in agriculture, stockbreeding or as biodiesel.Type: GrantFiled: August 6, 2009Date of Patent: October 8, 2013Assignee: HPD Process Engineering, S.A.Inventor: Daniel Irisarri Navalpotro
-
Patent number: 8545886Abstract: The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.Type: GrantFiled: August 13, 2007Date of Patent: October 1, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Wolfram Eisenreich, Thomas Friedl
-
Patent number: 8535716Abstract: A pharmaceutical composition is provided that includes an active ingredient in the form of a powder or granule, a water soluble high molecular weight excipient and a water insoluble hydrophilic amphiphilic excipient. These ingredients are solution mixed and dried to form a modified pharmaceutical ingredient in simultaneous contact with both the water soluble high molecular weight excipient and the water insoluble hydrophilic amphiphilic excipient. Adjuvants are compacted about the modified pharmaceutical ingredient as well as a release control agent. The release control agent being present at levels from 1 to 40 total weight percent of the pharmaceutical composition.Type: GrantFiled: April 1, 2005Date of Patent: September 17, 2013Assignee: TSRL, Inc.Inventors: John Hilfinger, Jae Seung Kim, Paul Kijek
-
Patent number: 8535799Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.Type: GrantFiled: February 27, 2007Date of Patent: September 17, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
-
Patent number: 8512744Abstract: Sustained release micropellets showing a stable controlled-release of a drug without being affected by the changes in pH value etc., characterized by being produced by coating core particles with a layer containing a water-soluble drug and further forming a film layer containing a water-insoluble polymer compound and a plasticizer on the thus obtained particles, locating a water-soluble filler layer between the water soluble drug-containing layer and the film layer, and having an average particle size of 300 ?m or less; medicinal compositions containing these micropellets; and a process for producing the same.Type: GrantFiled: August 16, 2007Date of Patent: August 20, 2013Assignee: Fujimoto Co., Ltd.Inventors: Fumio Yoneda, Fumiya Hamano, Eisaku Kitano, Tetsuya Hosono
-
Publication number: 20130209560Abstract: This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.Type: ApplicationFiled: February 23, 2011Publication date: August 15, 2013Applicant: CIMA LABS Inc.Inventors: Ehab Hamed, Carrie Kraling
-
Patent number: 8486448Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.Type: GrantFiled: December 16, 2008Date of Patent: July 16, 2013Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe LimitedInventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
-
Patent number: 8486449Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer.Type: GrantFiled: December 16, 2009Date of Patent: July 16, 2013Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe LimitedInventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
-
Patent number: 8465776Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.Type: GrantFiled: July 31, 2007Date of Patent: June 18, 2013Assignee: EthypharmInventor: Didier Hoarau
-
Patent number: 8454998Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: February 6, 2012Date of Patent: June 4, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Patent number: 8377474Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 26, 2008Date of Patent: February 19, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Patent number: 8372431Abstract: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.Type: GrantFiled: October 23, 2008Date of Patent: February 12, 2013Assignee: BIAL-Portela & C.A., S.A.Inventors: Teófilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
-
Patent number: 8372225Abstract: A method and apparatus for assembling a plurality of independently formed solid components is provided thereby forming a single delivery vehicle for a pharmaceutical or pharmaceutical-like product. The solid components can be held and fed to the apparatus via a plurality of magazines. Pusher rods and the like can be used for positioning each of the solid components. Where the components are connected via a bonding liquid, a sprayer is provided and compression pins or the like press the components with the bonding liquid together to form the final product. A rivet or other connection structure can also be used and driven through holes in each of the solid components to form the final product.Type: GrantFiled: November 17, 2006Date of Patent: February 12, 2013Assignee: Glaxo Group LimitedInventors: Thomas Bailey, Ronnie Benditt, Nigel Brewerton, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini, Paul Simmons
-
Patent number: 8357396Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.Type: GrantFiled: October 26, 2011Date of Patent: January 22, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
-
Patent number: 8337887Abstract: The present invention concerns a rapidly disintegrating taste-masked tablet having both hardness and non-friability properties comprising at least one active principle selected from the group of mineral salts, vitamins and mixtures thereof, the active principle being coated by a sweetening agent wherein the weight ratio of the active principle to the sweetening agent is from 0.2 to 3, and starch and microcrystalline cellulose in a weight ratio of starch to microcrystalline cellulose from about 0.76 to 0.85, and at least one free flow aid. It also concerns a method for the preparation of such a tablet.Type: GrantFiled: March 11, 2004Date of Patent: December 25, 2012Assignees: Laboratories Pharmaceutiques Rodael, Laboratories NutrisetInventor: Paul Equipart
-
Patent number: 8329216Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: June 29, 2006Date of Patent: December 11, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Haui-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 8309122Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: February 28, 2007Date of Patent: November 13, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 8293277Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: GrantFiled: June 22, 1999Date of Patent: October 23, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
-
Patent number: 8268351Abstract: A pharmaceutical matrix film tablet with controlled release of natural mixtures of conjugated estrogens which have been obtained from the urine of pregnant mares.Type: GrantFiled: June 14, 2004Date of Patent: September 18, 2012Assignee: Abbott Products GmbHInventors: Bernd Thumbeck, Klaus Budde, Gerhard Kristen, Margit Wiards
-
Publication number: 20120225122Abstract: This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: CIMA LABS INC.Inventors: Ehab HAMED, Manuel A. VEGA ZEPEDA
-
Patent number: 8226981Abstract: A method of preparing a taste-masking oral dosage form is provided. The method includes providing a first solution comprising a pharmaceutically active ingredient and a starch, providing a second solution comprising a hydrophilic polymer and a surfactant, blending the first and second solution to form a plurality of microparticles by a granulating process, wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch, and performing a compression-molding process to form the tablet.Type: GrantFiled: September 5, 2007Date of Patent: July 24, 2012Assignee: Medical and Pharmaceutical Industry Technology and Development CenterInventors: Chih-Chiang Yang, Wen-Che Wang, Hui-Yu Chen
-
Patent number: 8211466Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.Type: GrantFiled: February 17, 2010Date of Patent: July 3, 2012Assignee: Bioalliance PharmaInventors: Dominique Costantini, Caroline Lemarchand
-
Patent number: 8202456Abstract: Herein provided is a method for easily preparing a sustained release tablet which contains an orally administrable medicinal component, while maintaining the uniformity of the content of the medicinal component. The method comprises mixing (1) a granulated product A obtained by granulating an excipient and an enteric coating agent while spraying thereon with a solution or a suspension containing an orally administrable medicinal component, with (2) a composition B containing a hydrogel-forming substance; and then compressing the resulting mixture into a tablet.Type: GrantFiled: November 12, 2007Date of Patent: June 19, 2012Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Katashi Nakashima, Kazuo Kazama
-
Patent number: 8197850Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.Type: GrantFiled: November 19, 2001Date of Patent: June 12, 2012Assignee: Flamel TechnologiesInventors: Catherine Castan, Remi Meyrueix, Gerard Soula
-
Patent number: 8193226Abstract: Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form stabilized with regard to decomposition.Type: GrantFiled: October 27, 2008Date of Patent: June 5, 2012Assignees: Zhejiang Huahai Pharmaceutical Co., Ltd., Alfred E. Tiefenbacher GmbH & Co. KGInventors: Qiaomei Wu, Huiyan Gao, Hao Chen, Qiping Yan, Junqing Peng, Gongyun Hu
-
Patent number: 8119161Abstract: The present invention relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, and to said solid dosage form. In one embodiment it specifically relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent and/or carrier, wherein said solid dosage form is adapted to prevent moisture related degradation of said desmopressin.Type: GrantFiled: November 12, 2004Date of Patent: February 21, 2012Assignee: Ferring BVInventors: Kristin Wannerberger, Lars Anders Ragnar Nilsson
-
Patent number: 8114435Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.Type: GrantFiled: February 9, 2009Date of Patent: February 14, 2012Assignee: AstraZeneca ABInventors: Helene Depui, Per Lundberg
-
Patent number: 8071128Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.Type: GrantFiled: June 20, 2003Date of Patent: December 6, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
-
Patent number: 7998506Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.Type: GrantFiled: May 23, 2003Date of Patent: August 16, 2011Assignee: KOS Life Sciences, Inc.Inventor: David J Bova
-
Publication number: 20110171302Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.Type: ApplicationFiled: March 25, 2011Publication date: July 14, 2011Applicant: Center Laboratories, Inc.Inventors: Guang-Tzuu SHANE, Chien-Fen Chen, Chuen-Lin Din, Hui-Ling Tsai, Pei-Chen Tsai
-
Patent number: 7964216Abstract: The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus.Type: GrantFiled: January 11, 2002Date of Patent: June 21, 2011Assignee: Sun Pharma Advanced Research Company LimitedInventors: Dilip Shantilal Shanghvi, Kirti Wardhaman Ganorkar, Yashoraj Rupsinh Zala, Nitin Bhalachandra Dharmadhikari, Satish C Khanna
-
Publication number: 20110129530Abstract: There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.Type: ApplicationFiled: November 30, 2010Publication date: June 2, 2011Applicant: EURAND, INC.Inventors: Gopi M. Venkatesh, Jin-Wang Lai, James M. Clevenger, Craig Kramer
-
Patent number: 7943172Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.Type: GrantFiled: August 14, 2006Date of Patent: May 17, 2011Assignee: Siegfried Generics International AGInventors: Lambert Tillmann Röhrich, Beat W. Müller
-
Patent number: 7943171Abstract: A method for preparing granules of active substances containing food fibers which consists in granulating the active substances mixed with branched malto-dextrins having between 15 and 35% of 1-6 glucoside bonds, a reducing sugar content less than 20%, a polymolecularity index less than 5 and a number average molecular weight Mn equal or less than 4500 g/mol, the branched malto-dextrins constituting between 3 and 13 wt. % of the mixture to be granulated.Type: GrantFiled: October 24, 2003Date of Patent: May 17, 2011Assignee: Roquette FreresInventor: Michel Serpelloni
-
Patent number: 7939102Abstract: Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.Type: GrantFiled: June 2, 2003Date of Patent: May 10, 2011Assignees: Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Torrent Research CenterInventors: Sunil Sadanand Nadkarni, Navin Vaya
-
Patent number: 7875292Abstract: An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 ?m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.Type: GrantFiled: May 7, 2008Date of Patent: January 25, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshihiro Shimizu, Shuji Morimoto, Tetsuro Tabata
-
Patent number: 7846476Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.Type: GrantFiled: May 2, 2002Date of Patent: December 7, 2010Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
-
Patent number: 7842311Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.Type: GrantFiled: October 21, 2003Date of Patent: November 30, 2010Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Patent number: 7820198Abstract: One aspect of the present invention is directed to a solid chemical tablet in a shape comprising an elongated cylindrical side surface and an elongated flat side surface or an elongated concave cut side surface. Another aspect of the present invention is directed to a solid chemical tablet comprising a blend of hydrated calcium hypochlorite with magnesium sulfate heptahydrate. This invention further relates to a solid chemical tablet comprising a blend of solid calcium hypochlorite, and one or more solid alkali metal phosphate.Type: GrantFiled: October 19, 2004Date of Patent: October 26, 2010Assignee: Arch Chemicals, Inc.Inventors: David W. Blanchette, G. Warren Ginn
-
Patent number: 7790197Abstract: A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.Type: GrantFiled: April 20, 2004Date of Patent: September 7, 2010Assignee: Warner-Lambert Company LLCInventors: Michael B. Fergione, Barbara A. Johnson, Kenneth Craig Waterman
-
Patent number: 7771745Abstract: The present invention provides a method for making a fast dissolving tablet. The method includes the steps of (a) preparing a first solution containing a hydrophilic polymer and a starch; (b) preparing a second solution containing a pharmaceutically active ingredient and a surfactant; (c) blending the first and the second solution together to form a plurality of granule powders by granulation; (d) mixing the granule powders with excipients; and (e) applying a compression-molding process to form the fast dissolving tablet.Type: GrantFiled: May 3, 2004Date of Patent: August 10, 2010Assignee: Pharmaceutical Industry Technology and Development CenterInventors: Wen-Che Wang, Hui-Yu Chen, Chih-Chiang Yang
-
Patent number: 7771746Abstract: A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.Type: GrantFiled: November 19, 2004Date of Patent: August 10, 2010Assignee: Polichem SAInventor: Federico Mailland
-
Patent number: 7767227Abstract: The present invention relates to a novel sustained-release oral galenical form of molsidomine for the treatment of all forms of angina attack (angina of effort, spastic angina, mixed angina). According to the invention, this novel galenical form contains a therapeutically effective amount of molsidomine or one of its active metabolites and has an in vitro dissolution rate [measured spectrophotometrically at 286 or 311 nm by the method described in the European Pharmacopoeia, 3rd edition (or USP XXIV), at 50 rpm, in 500 ml of a 0.1 N HCl medium, at 37° C.] of: 15 to 25% of molsidomine released after 1 hour, 20 to 35% of molsidomine released after 2 hours, 50 to 65% of molsidomine released after 6 hours, 75 to 95% of molsidomine released after 12 hours, >85% of molsidomine released after 18 hours and >90% of molsidomine released after 24 hours, the plasma peak of molsidomine obtained in vivo occurring 2.Type: GrantFiled: February 22, 2001Date of Patent: August 3, 2010Assignee: Therabel Pharmaceuticals LimitedInventor: Jozsef-Michel Geczy
-
Publication number: 20100143468Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.Type: ApplicationFiled: February 26, 2010Publication date: June 10, 2010Applicant: Xanodyne Pharmaceuticals, Inc.Inventors: Keith A. MOORE, Ralph A. Heasley, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest
-
Patent number: RE42096Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: March 24, 2005Date of Patent: February 1, 2011Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic